Neuro-Oncology News

The FDA has granted orphan drug designation to therapies for six hematology/oncology drug indications.

Twelve institutions across the United States and Canada formed a collaborative designed to improve long-term survival and quality of life for patients with malignant brain tumors.

Continued VB-111 monotherapy priming after progression with bevacizumab combination treatment improved survival outcomes among patients with recurrent glioblastoma, according to results of a phase 1/phase 2 study published in Neuro-Oncology.

Click here to read the Cover Story, “Right to Try: A ‘well-intentioned’ but ‘misguided’ law.”

Partial or total resection appeared associated with longer OS compared with biopsy alone among a cohort of adults with brainstem high-grade gliomas, according to study results published in Journal of Neuro-Oncology.

All-cause and cancer-specific mortality rates have declined overall among adolescent and young adult cancer survivors during the past 4 decades, according to results of a retrospective study published in Journal of the National Cancer Institute.

Patient survival is the overarching goal of all cancer treatments, and improvements in survival that have been achieved over the years are an unequivocal victory for oncology.

The Mark Foundation for Cancer Research presented grants to six early career scientists who are conducting research projects designed to address unmet needs.

Maximal resection of the contrast-enhanced tumor appeared associated with longer OS among all subgroups of patients with glioblastoma, according to results of a retrospective study published in JAMA Oncology.

ASCO has named the refinement of surgical treatment of cancer as the Advance of the Year, recognizing emerging novel systemic therapies that changed the role of cancer surgery.